David Hansen
President and CEO at MabVax Therapeutics
- Role
- President and CEO at Mabvax Therapeutics, Inc
- Location
- San Diego, CA, US
- LinkedIn followers
- 500 followers
About David Hansen
J. David Hansen has served as MabVax’s President, Chief Executive Officer, and Member of…
Experience
President and CEO
Jan 2006 — Present · San Diego, CA, US
MabVax Therapeutics Holdings, Inc.(OTCQB: MBVX) is a differentiated immuno-oncology development company with a proprietary approach to harnessing the human immune system to treat and diagnose cancer. MabVax is advancing a pipeline of human monoclonal antibody (HuMab) products based upon the protective immune responses generated by patients who have been immunized against targeted cancers with the company’s proprietary vaccines. MabVax has an exclusive license to these therapeutic vaccines from Memorial Sloan Kettering Cancer Center (MSK). MabVax has initiated two Phase I clinical trials, MVT- 5873 as a therapeutic antibody and MVT-2163 as a companion immuno-PET imaging agent for metastatic pancreatic cancer. MabVax plans to initiate a Phase I clinical trial for a HuMab-5B1 antibody-based radioimmunotherapy agent early next year and has multiple follow on programs.
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.